Sign In
Buy HAE
$65.88
-0.490 (-0.738%)
At Close: Jun 03, 2026
Haemonetics (HAE) Earnings Expected to Grow: Should You Buy?
02:01pm, Monday, 31'st Oct 2022 Zacks Investment Research
Haemonetics (HAE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Haemonetics (HAE) is Poised to Beat Earnings Estimates Again
04:10pm, Friday, 28'th Oct 2022 Zacks Investment Research
Haemonetics (HAE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why Haemonetics (HAE) is Poised to Beat Earnings Estimates Again
01:33pm, Friday, 28'th Oct 2022
Haemonetics (HAE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Centene (CNC) to Post Q3 Earnings: What's in the Cards?
04:06pm, Thursday, 20'th Oct 2022 Zacks Investment Research
Centene's (CNC) third-quarter results are likely to reflect higher premiums and contract wins enjoyed by its Medicaid business, partly offset by escalating operating expenses.
Expert Ratings for Haemonetics
05:09pm, Thursday, 13'th Oct 2022 Benzinga
Over the past 3 months, 6 analysts have published their opinion on Haemonetics (NYSE:HAE) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a compan
Benzinga's Top Ratings Upgrades, Downgrades For October 13, 2022
02:05pm, Thursday, 13'th Oct 2022 Benzinga
Upgrades
TD Securities upgraded the previous rating for BCE Inc (NYSE:BCE) from Hold to Buy. In the second quarter, BCE showed an EPS of $0.68, compared to $0.68 from the year-ago quarter. The current
Is Amphastar Pharmaceuticals (AMPH) Outperforming Other Medical Stocks This Year?
01:40pm, Monday, 10'th Oct 2022 Zacks Investment Research
Here is how Amphastar Pharmaceuticals (AMPH) and Haemonetics (HAE) have performed compared to their sector so far this year.
Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2023 Results: November 7, 2022
04:05pm, Thursday, 06'th Oct 2022
BOSTON , Oct. 6, 2022 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish second quarter fiscal year 2023 financial results at 6:00 am ET on Monday, Novem
Leading Medical Stocks, Including Sensus And Shockwave, Have Grown At Least 36% This Year
01:18pm, Wednesday, 05'th Oct 2022
Biotech isn't the only place investors in health care stocks can make money in 2022. Take a look at leading medical-equipment stocks.
Haemonetics (HAE) Hospital Arm Aids, Macro Issues Persist
03:40pm, Friday, 30'th Sep 2022 Zacks Investment Research
Robust performance of Haemonetics' (HAE) Hospital business, on continued strength in the Hemostasis Management product line, instills optimism.
Here's Why Haemonetics (HAE) is a Strong Growth Stock
01:45pm, Friday, 30'th Sep 2022 Zacks Investment Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Haemonetics (HAE) Hospital Arm Aids, Macro Issues Persist
12:48pm, Friday, 30'th Sep 2022
Robust performance of Haemonetics' (HAE) Hospital business, on continued strength in the Hemostasis Management product line, instills optimism.
Here's Why Haemonetics (HAE) is a Strong Growth Stock
11:18am, Friday, 30'th Sep 2022
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Haemonetics (HAE) to Offer Two VASCADE Devices in the EU
05:41pm, Wednesday, 14'th Sep 2022 Zacks Investment Research
Haemonetics' (HAE) VASCADE and VASCADE MVP devices help patients attain hemostasis more quickly and with lesser complications.
Haemonetics (HAE) to Offer Two VASCADE Devices in the EU
02:59pm, Wednesday, 14'th Sep 2022
Haemonetics' (HAE) VASCADE and VASCADE MVP devices help patients attain hemostasis more quickly and with lesser complications.
